On this page

Cromolyn Sodium

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Cromolyn Sodium
Generic name
Cromolyn Sodium
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Proficient Rx LP
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
4
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Cromolyn Sodium 40 mg/mL 831109 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
8

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased Histamine Release [PE] PE All 16 members
Mast Cell Stabilizer [EPC] EPC All 16 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
075282
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 16, 1999
Sponsor
SANDOZ
Products on application
1
Submissions recorded
6
Products approved under application 075282.
Product Trade name Form Strength Ingredient Status TE Flags
075282-001 CROMOLYN SODIUM SOLUTION/DROPS CROMOLYN SODIUM Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 075282.
Type No. Action Status Date Review
Supplement 5 Manufacturing (CMC) Approved December 23, 2002 —
Supplement 4 Manufacturing (CMC) Approved October 1, 2002 —
Supplement 3 Manufacturing (CMC) Approved March 28, 2002 —
Supplement 2 Manufacturing (CMC) Approved April 7, 2000 —
Supplement 1 Manufacturing (CMC) Approved October 7, 1999 —
Original application 1 Approved June 16, 1999 —

Review documents

  • 0 · Original application · June 16, 1999

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260401). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260401 HUMAN PRESCRIPTION DRUG · 20191001

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of cromolyn sodium ophthalmic solution therapy is dependent upon its administration at regular intervals, as directed. Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement. If required, corticosteroids may be used concomitantly with Cromolyn Sodium Ophthalmic Solution USP, 4%.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Cromolyn Sodium Ophthalmic Solution USP, 4% is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The most frequently reported adverse reaction attributed to the use of cromolyn sodium ophthalmic solution, on the basis of reoccurrence following readministration, is transient ocular stinging or burning upon instillation. The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributable to the drug: Conjunctival injection; watery eyes; itchy eyes; dryness around the eye; puffy eyes; eye irritation; and styes. Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema and rash.

Description

openFDA Drug Labeling

DESCRIPTION Cromolyn Sodium Ophthalmic Solution USP, 4% is a clear, colorless, sterile solution intended for topical ophthalmic use. Cromolyn sodium is represented by the following structural formula: Chemical Name: Disodium 5-5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-carboxylate] Pharmacologic Category: Mast cell stabilizer. EACH mL CONTAINS: Active: cromolyn sodium 40 mg (4%); Preservative: benzalkonium chloride 0.01%. Inactives: edetate disodium 0.1% and purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (4.0-7.0). chemicalstructure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Cromolyn Sodium Ophthalmic Solution USP, 4% is supplied in a white, opaque, plastic ophthalmic dispenser in the following sizes: 10 mL NDC 71205-230-10 Storage: Store between 15° - 30°C (59°- 86°F). Protect from light-store in original carton. Keep tightly closed and out of the reach of children. Rx Only

Adverse event reports

Source: openFDA FAERS
3,585
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CROMOLYN SODIUM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-1202-0 50090-1202 A-S Medication Solutions 10 mL in 1 BOTTLE, PLASTIC (50090-1202-0) November 28, 2014
68788-8490-1 68788-8490 Preferred Pharmaceuticals Inc. 10 mL in 1 BOTTLE, PLASTIC (68788-8490-1) July 21, 2023
71205-230-10 71205-230 Proficient Rx LP 10 mL in 1 BOTTLE, PLASTIC (71205-230-10) March 1, 2019
61314-237-10 61314-237 Sandoz Inc 1 BOTTLE, PLASTIC in 1 CARTON (61314-237-10) / 10 mL in 1 BOTTLE, PLASTIC June 29, 1999
50090-1202 50090-1202 A-S Medication Solutions — June 29, 1999
68788-8490 68788-8490 Preferred Pharmaceuticals Inc. — July 21, 2023
71205-230 71205-230 Proficient Rx LP — June 29, 1999
61314-237 61314-237 Sandoz Inc — June 29, 1999

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.